BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 StudyRosa Ayala, David Lavie, Adi Shacham Abulafia et al.|Blood|2022Cited by 4